NEWARK, Del.--(BUSINESS WIRE)--Strategic Diagnostics Inc. (Nasdaq: SDIX) - a leading provider of biotechnology-based detection solutions for a broad range of life science and industrial applications, today reported financial results for the quarter ended June 30, 2009. Revenues for the quarter were $6.9 million, compared to $6.6 million for the same period in 2008. Revenues for the second quarter of 2009 were positively impacted by a 16% quarter-over-comparative quarter increase in life science revenues, with a 45% quarter-over-comparative quarter increase in sales of Genomic Antibody Technology™ (GAT™) products.
